Evidence map›Paper›PMID 38381460›Full record

ArticlemAbs

Production of antibodies and antibody fragments containing non-natural amino acids in

Jacquelyn Blake-Hedges, Dan Groff, Wilson Foo, Jeffrey Hanson, Elenor Castillo, Miao Wen, Diana Cheung, Mary Rose Masikat, Jian Lu, Young Park and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Jacquelyn Blake-HedgesResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Dan GroffResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Wilson FooResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Jeffrey HansonResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Elenor CastilloResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Miao WenResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Diana CheungResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Mary Rose MasikatResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Jian LuResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Young ParkResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Nina Abi CarlosResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Hans UsmanResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Kevin FongResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Abigail YuResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Sihong ZhouResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Joyce KwongResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Cuong TranResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Xiaofan LiResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Dawei YuanResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Trevor HallamResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Gang YinResearch and Process Development, Sutro Biopharma, Inc, South San Francisco, CA, USA.
Sutro Biopharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic bioconjugates are emerging as an essential tool to combat human disease. Site-specific conjugation technologies are widely recognized as the optimal approach for producing homogeneous drug products. Non-natural amino acid (nnAA) incorporation allows the introduction of bioconjugation handles at genetically defined locations.

Indexed as

Amino AcidsEscherichia coliAntibodiesHumansImmunoglobulin FragmentsAmino AcidsAntibodiesImmunoglobulin FragmentsAntibody–drug conjugatebioconjugatione. coli expressionnon-natural amino acidsite-specifictherapeutic protein

Identifiers

PMID38381460
PMCPMC10883104
OpenAlexW4391994415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.